130 related articles for article (PubMed ID: 38452649)
1. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
[TBL] [Abstract][Full Text] [Related]
2. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
4. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.
Conway S; Gupta S; Healy B; Chuang TY; Stazzone L; Sullivan J; Polgar-Turcsanyi M; Chitnis T; Houtchens M
Mult Scler Relat Disord; 2024 Jul; 87():105680. PubMed ID: 38795595
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
6. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
7. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
Conte WL; Golzarri-Arroyo L
Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
[TBL] [Abstract][Full Text] [Related]
8. Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
Kwon S; Han KD; Jung JH; Cho EB; Chung YH; Park J; Choi HL; Jeon HJ; Shin DW; Min JH
Mult Scler; 2024 May; 30(6):714-725. PubMed ID: 38561953
[TBL] [Abstract][Full Text] [Related]
9. Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study.
Desai A; Hashash JG; Kochhar GS; Farraye FA
Crohns Colitis 360; 2023 Jul; 5(3):otad047. PubMed ID: 37680248
[TBL] [Abstract][Full Text] [Related]
10. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
[TBL] [Abstract][Full Text] [Related]
12. Latent tuberculosis infection in Korean patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
Kim KH; Kim SH; Park NY; Kim MJ; Hyun JW; Kim HJ
Mult Scler Relat Disord; 2024 Jan; 81():105145. PubMed ID: 38039942
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
[TBL] [Abstract][Full Text] [Related]
14. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection.
Stastna D; Menkyova I; Drahota J; Hrnciarova T; Kubala Havrdova E; Vachova M; Andelova M; Kleinova P; Kovarova I; Krasulova E; Preiningerova JL; Novakova I; Novotna K; Novotna M; Nytrova P; Pavlickova J; Srpova B; Storey K; Ticha V; Tyblova M; Uher T; Vodehnalova K; Horakova D
Mult Scler Relat Disord; 2022 Sep; 65():104014. PubMed ID: 35803085
[TBL] [Abstract][Full Text] [Related]
15. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic.
Rath L; Yeh WZ; Roldan A; Wesselingh R; Zhong M; Tan T; Seery N; Bridge F; Foong Y; Skibina O; Nesbitt C; Butzkueven H; Monif M; van der Walt A
BMJ Neurol Open; 2024; 6(1):e000667. PubMed ID: 38736583
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract][Full Text] [Related]
18. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
[No Abstract] [Full Text] [Related]
19. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
